结构心臟器械市场- 按产品（心臟瓣膜装置、封堵器和输送系统、瓣环成形术环）、按程序（更换、修復）、最终用途（医院、ASC、心导管实验室） - 全球预测， 2024 年- 2032 年

由于应用范围的扩大和新产品的不断开发，结构心臟器材市场规模预计在 2024 年至 2032 年间以 8.8% 的CAGR扩大。

除了瓣膜置换和修復等传统手术之外，结构性心臟装置也用于治疗多种疾病，包括心房中隔缺损 (ASD)、卵圆孔未闭 (PFO) 和左心耳封堵术 (LAAC)。此外，设备技术的不断进步正在导致新型材料、改进的输送系统和增强的成像技术的开发。例如，2024 年 3 月，雅培在美国推出了最新版本的 Navitor 心臟瓣膜技术，与上一型号相比进行了多项改进。此类新产品的开发旨在提高功效、安全性和结果，推动了全球对结构心臟设备的需求。

该行业分为产品、程序、最终用途和地区。

根据产品，瓣环成形环领域的市占率预计将从 2024 年至 2032 年以 9.1% 的CAGR获得显着成长。这些环在心臟瓣膜修復和置换手术中发挥着至关重要的作用，特别是在二尖瓣和三尖瓣手术中。瓣膜性心臟病的盛行率不断上升，加上微创手术技术的日益普及，将推动对瓣环成形术环的需求，为心臟瓣膜提供结构支撑，以改善其功能和耐用性。此外，环设计、材料和技术的进步也推动了该领域的成长。

就最终用途而言，心导管实验室领域的结构性心臟器械市场在2023 年产生了可观的收入，预计到2032 年增长率将达到9.1%。心导管实验室处于结构性心臟病微创手术的前沿，如经导管主动脉瓣置换术（TAVR）和经导管二尖瓣修復术（TMVR）。心血管疾病的盛行率不断上升以及对微创治疗方案的偏好正在推动这些专业设施对结构性心臟设备的需求。

考虑到区域格局，在心血管疾病盛行率上升、人口老化和生活方式改变的推动下，亚太地区结构心臟器械产业2024年至2032年的CAGR将达到9.9%。此外，经济状况的改善和医疗保健支出的增加正在促进该地区先进心臟手术的采用。因此，中国、印度、日本和韩国等国家正成为结构性心臟器械製造商的重要中心。医疗保健基础设施的进步、先进医疗技术的普及以及熟练医疗保健专业人员数量的不断增加正在进一步推动区域市场的扩张。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 心血管疾病负担日益加重
    • 技术进步
    • 有利的报销方案
    • 对微创手术的偏好不断上升
  • 产业陷阱与挑战
    • 严格的监理政策
    • 潜在的併发症和不良事件
• 成长潜力分析
• 波特的分析
• PESTEL分析
• 2023 年定价分析
• 报销场景
• 监管环境
• 技术景观
• 未来市场趋势
• 缺口分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按产品分类，2018 年 - 2032 年

• 主要趋势
• 心臟瓣膜装置
  • 外科心臟瓣膜
  • 经导管心臟瓣膜
• 瓣环成形术环
• 封堵器和输送系统
• 其他产品

第 6 章：市场估计与预测：按程序，2018 年 - 2032 年

• 主要趋势
• 更换程序
  • 主动脉瓣置换手术 (SAVR)
  • 经导管主动脉瓣置换术 (TAVR)
  • 经导管二尖瓣置换术 (TMVR)
  • 其他更换流程
• 维修程序
  • 左心耳封堵术 (LAAC)
  • 经导管二尖瓣修復术 (TMVr)
  • 经导管三尖瓣修復术 (TTVR)
  • 瓣膜成形术
  • 其他维修程序

第 7 章：市场估计与预测：按最终用途，2018 - 2032 年

• 主要趋势
• 医院
• 门诊手术中心
• 心导管实验室
• 其他最终用户

第 8 章：市场估计与预测：按地区划分，2018 年 - 2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• Abbott Laboratories
• AtriCure, Inc.
• Biomerics, LLC
• Boston Scientific Corporation
• Braile Biomedica
• Cryolife Inc.
• Edwards Lifesciences Corporation
• JenaValve Technology, Inc.
• Lepu Medical Technology(Beijing)Co.,Ltd.
• LivaNova PLC
• Medtronic plc
• NuMed Inc.

Structural Heart Devices Market size is poised to expand at 8.8% CAGR between 2024 and 2032 due to the expanding application scope and continuous new product developments.

Beyond traditional procedures, such as valve replacements and repairs, structural heart devices are used for treating a wide range of conditions, including atrial septal defects (ASDs), patent foramen ovale (PFO), and left atrial appendage closures (LAAC). Moreover, the ongoing advancements in device technologies are leading to the development of novel materials, improved delivery systems, and enhanced imaging techniques. For instance, in March 2024, Abbott introduced the most recent version of its Navitor heart valve technology in the U.S. with several improvements over the last model. Such new product developments to offer improved efficacy, safety, and outcomes are fueling the demand for structural heart devices worldwide.

The industry is segmented into product, procedure, end-use, and region.

Based on product, the market share from the annuloplasty rings segment is projected to gain significant traction at 9.1% CAGR from 2024-2032. These rings play a vital role in surgical procedures for heart valve repair and replacement, particularly in mitral and tricuspid valve surgeries. The rising prevalence of valvular heart diseases coupled with the increasing adoption of minimally invasive surgical techniques will drive the demand for annuloplasty rings to provide structural support to the heart valves for improving their function and durability. Furthermore, advancements in ring designs, materials, and technologies are also propelling the segment growth.

With respect to end-use, the structural heart devices market from the cardiac catheterization labs segment generated considerable revenue in 2023 and is estimated to witness 9.1% growth rate through 2032. Cardiac catheterization labs are at the forefront of minimally invasive procedures for structural heart conditions, such as transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve repair (TMVR). The increasing prevalence of cardiovascular diseases and the preference for less invasive treatment options are fueling the demand for structural heart devices in these specialized facilities.

Given the regional landscape, the Asia Pacific structural heart devices industry is set to exhibit 9.9% CAGR from 2024-2032 driven by the rising prevalence of cardiovascular diseases, coupled with the aging population and changing lifestyles. Moreover, the improving economic conditions and increasing healthcare expenditure are facilitating the adoption of advanced cardiac procedures across the region. As a result, countries including China, India, Japan, and South Korea are becoming significant hubs for structural heart device manufacturers. Advancements in healthcare infrastructure, access to sophisticated medical technologies, and the growing number of skilled healthcare professionals are further driving the regional market expansion.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast calculations
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing burden of cardiovascular diseases
    • 3.2.1.2 Technological advancements
    • 3.2.1.3 Favorable reimbursement scenario
    • 3.2.1.4 Rising preference for minimally invasive procedures
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Stringent regulatory policies
    • 3.2.2.2 Potential complications and adverse events
• 3.3 Growth potential analysis
• 3.4 Porter's analysis
  • 3.4.1 Supplier power
  • 3.4.2 Buyer power
  • 3.4.3 Threat of new entrants
  • 3.4.4 Threat of substitutes
  • 3.4.5 Industry rivalry
• 3.5 PESTEL analysis
• 3.6 Pricing analysis, 2023
• 3.7 Reimbursement scenario
• 3.8 Regulatory landscape
• 3.9 Technological landscape
• 3.10 Future market trends
• 3.11 GAP analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Heart valve devices
  • 5.2.1 Surgical heart valves
  • 5.2.2 Transcatheter heart valves
• 5.3 Annuloplasty rings
• 5.4 Occluders & delivery systems
• 5.5 Other products

Chapter 6 Market Estimates and Forecast, By Procedure, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Replacement procedures
  • 6.2.1 Surgical aortic valve replacement (SAVR)
  • 6.2.2 Transcatheter aortic valve replacement (TAVR)
  • 6.2.3 Transcatheter mitral valve replacement (TMVR)
  • 6.2.4 Other replacement procedures
• 6.3 Repair procedures
  • 6.3.1 Left atrial appendage closure (LAAC)
  • 6.3.2 Transcatheter mitral valve repair (TMVr)
  • 6.3.3 Transcatheter tricuspid valve repair (TTVr)
  • 6.3.4 Valvuloplasty
  • 6.3.5 Other repair procedures

Chapter 7 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Ambulatory surgical centers
• 7.4 Cardiac catheterization labs
• 7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories
• 9.2 AtriCure, Inc.
• 9.3 Biomerics, LLC
• 9.4 Boston Scientific Corporation
• 9.5 Braile Biomedica
• 9.6 Cryolife Inc.
• 9.7 Edwards Lifesciences Corporation
• 9.8 JenaValve Technology, Inc.
• 9.9 Lepu Medical Technology(Beijing)Co.,Ltd.
• 9.10 LivaNova PLC
• 9.11 Medtronic plc
• 9.12 NuMed Inc.